المساهمون: Joshua Cook, Assistant Professor of Medicine at the Columbia University Medical Center

المصدر: Bile Acid and Lipid Metabolism in Patients With Drug-induced Acute Insulin Resistance

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05571670Test

المساهمون: Heinz-Josef Klumpen, MD

المصدر: Phase I Study of Nelfinavir in Combination With Temsirolimus in the Treatment of Patients With Advanced Cancers, Including Second Line Renal Cell Cancer

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT01079286Test

المؤلفون: The Leukemia and Lymphoma Society

المصدر: Teachey DT, Sheen C, Hall J, Ryan T, Brown V Fh J, Re GS, Se AE, Norr R, Chang YJ, Carroll M, Grupp SA. mTOR hors are synergt wh methotrexate: an effecte combatn to treat acute lymphoblast leukem. Blood. 2008 Sep 1;112(5):2020-3. do 10.1182/blood-2008-02-137141. Epub 2008 Jun 10.
Houghton PJ, Morton CL, Kolb EA, Gorlk R, Lock R, Carol H, Reynolds CP, Mar JM, Ke ST, Blups CA, Smh MA. l testg (stage 1) of the mTOR hor rapamyc by the pedtr preclal testg program. Pedtr Blood Cancer. 2008 Apr;50(4):799-805. do 10.1002/pbc.21296.
Teachey DT, Obzut DA, Cooperman J, Fang J, Carroll M, ChoJK, Houghton PJ, Brown V Grupp SA. The mTOR hor CC779 duces apoptos and hs growth preclal models of prary adult human ALL. Blood. 2006 Feb 1;107(3):1149-55. do 10.1182/blood-2005-05-1935. Epub 2005 Sep 29.
Brown V Fang J, Alcorn K, Barr R, K JM, Wasserman R, Grupp SA. Rapamyc acte agast B-precursor leukem vro and vo, an effect that modulated by -7-medted snalg. Proc Natl Acad ScU S A. 2003 Dec 9;100(25):15113-8. do 10.1073/pnas.2436348100. Epub 2003 Dec 1.
Luger S, Perl A, Kemner A. A phase dose escalatn study of the mTOR hor solus and MEC chemotherapy targetg snal transductn leukem stem cells for acute myelo leukem. . Blood. 2006;106:161.
Morron DJ, Hogan LE, Condos G, Bhatla T, Germo N, Moskowz NP, Lee L, BhojwanD, Horton TM, Belskaya-Levy Greenberger LM, Horak , Grupp SA, Teachey DT, Raetz EA, Carroll WL. Endogenous knockdown of surv proves chemotherapeut response ALL models. Leukem. 2012 Feb;26(2):271-9. do 10.1038/leu.2011.199. Epub 2011 Aug 16.
Sheen C, Vcent T, Barrett D, Horwz EM, Hult J, Strong E, Grupp SA, Teachey DT. Stats are acte acute lymphoblast leukaem (ALL): a therapy that may treat ALL and prevent avascular necros. Br J Haematol. 2011 Nov;155(3):403-7. do 10.1111/j.1365-2141.2011.08696.x. Epub 2011 May 9. No abstract avaable.
Barrett D, Brown V Grupp SA, Teachey DT. Targetg the PK/AKT/mTOR snalg ax chdren wh hematolog malnancs. Paedtr Drugs. 2012 Oct 1;14(5):299-316. do 10.2165/11594740-000000000-00000.
Phase 2 Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT01162551Test

المؤلفون: Pfizer

المساهمون: Bradley Carthon MD, PhD, Principal Investigator

المصدر: Phase I Study of Axitinib and Temsirolimus in Solid Tumors

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT01529138Test